3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Multiple Myeloma
8
Neoplasms
7
Colorectal Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Ovarian Neoplasms
5
Breast Neoplasms
5
Recurrence
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Melanoma
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Glioma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Sarcoma
3
Salivary Gland Neoplasms
3
Pheochromocytoma
3
Paraganglioma
3
Neuroendocrine Tumors
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Lung Neoplasms
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
3
Hematologic Neoplasms
3
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Has announcements
×
Diffuse Large B-Cell Lymphoma Refractory
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA